Analysis of neuropathology of localization-related epilepsy and other childhood-onset neurological disorders by PET using an inflammatory ligand, [11C]-DPA713

Analysis of corresponding neuropathology of localization-related epilepsy and other childhood-onset neurological disorders by PET using an inflammatory ligand, [11C]-DPA713 - Analysis of neuropathology of localization-related epilepsy and other childhood-onset neurological disorders using an inflammatory radio-isotope ligand

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024167

Enrollment

125

Registered

2016-10-15

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

localization related epilepsy and other childhood-onset neurological disorders

Interventions

[11C]-DPA713 PET-CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with localization related epilepsy and other childhood-onset neurological disorders (>1 year-old of age), who are treated in Pediatrics and/or Neurosurgery in Osaka University Hospital. 2)The patients who or whose caregivers gave written informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients with severe hepatic and/or renal dysfunction 2) Woman who is pregnant, breast-feeding and may become pregnant. 3) The patients whose attending physician jugged that participating in this study as inadequacy.

Design outcomes

Primary

Measure	Time frame
We will qualitatively estimate the uptake of [11C]-DPA713 in a human brain.	—

Secondary

Measure	Time frame
1)We will analyze the association of [11C]DPA713 data and other clinical data, such as clinical manifestation, EEG, MRI, FDG-PET, Iomazenil-SPECT, and MEG. 2)In the patients who undergo epilepsy surgery, the severity of microglial activation is by a neuropathological way. 3) We study the association of neuroinflammation in child-onset neurological disorders. 4) We analyze the efficacy on the neuroinflammation by anti-inflammatory therapy.	—

Measure

Time frame

1)We will analyze the association of [11C]DPA713 data and other clinical data, such as clinical manifestation, EEG, MRI, FDG-PET, Iomazenil-SPECT, and MEG. 2)In the patients who undergo epilepsy surgery, the severity of microglial activation is by a neuropathological way. 3) We study the association of neuroinflammation in child-onset neurological disorders. 4) We analyze the efficacy on the neuroinflammation by anti-inflammatory therapy.

—

Countries

Japan

Contacts

Public ContactShimono Kuriko

Osaka University Hospital Pediatrics

kuriko@ped.med.osaka-u.ac.jp06-6879-3863

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026